Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149871 (
deep vein thrombosis
)
12,364
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Pediatric lower extremity
deep vein thrombosis
(LE-DVT) can lead to postthrombotic syndrome (PTS) and other adverse events. We investigated the outcomes of LE-
DVT
in children. Three groups were compared: non-line-related (Non-LR)
DVT
, LR
DVT
in neonates (LR
neonates
), and LR
DVT
in non-neonates (LR
non-neonates
). A total of 339 children were included (Non-LR, n = 56; LR
neonates
, n = 95; and LR
non-neonates
, n = 188). We found a statistically significant difference in the frequency of PTS (
P
= .04; 62.5%, 40.0%, and 46.3% in Non-LR, LR
neonates
, and LR
non-neonates,
respectively), of recurrent LE-
DVT
(
P
= .001; 10.7% and 2.0% in Non-LR and LR
non-neonates,
respectively), and pulmonary embolism (PE) (
P
< .001; 19.6% and 3.2% in Non-LR and LR
non-neonates,
respectively) among groups. There was no difference in
DVT
resolution (
P
= .41). Multivariable analysis showed that
DVT
resolution, triggering event, and sex predicted Modified Villalta Scale (
MVS
; for pediatric PTS) scores >1; there was an interaction between
DVT
triggering event and sex. The time to reach an
MVS
>1 was significantly different when comparing groups (log-rank test,
P
< .001). Moreover, we found a significant difference in baseline
MVS
scores among groups, but the difference did not appear to change over time. In conclusion, LR LE-
DVT
had more benign outcomes than Non-LR
DVT
. Sex,
DVT
triggering event, and
DVT
resolution predicted LE-PTS in our cohort.
...
PMID:Postthrombotic syndrome and other outcomes of lower extremity deep vein thrombosis in children. 2883 30
